Cook, Gary
Cook, Gary, 1961-
Gary Cook researcher
VIAF ID: 116013152 (Personal)
Permalink: http://viaf.org/viaf/116013152
Preferred Forms
- 200 _ | ‡a Cook ‡b Gary
- 100 1 _ ‡a Cook, Gary
- 100 1 _ ‡a Cook, Gary
-
-
-
- 100 1 _ ‡a Cook, Gary ‡d 1961-
- 100 1 _ ‡a Cook, Gary ‡d 1961-
- 100 1 _ ‡a Cook, Gary, ‡d 1961-
-
- 100 0 _ ‡a Gary Cook ‡c researcher
4xx's: Alternate Name Forms (6)
5xx's: Related Names (7)
- 510 2 _ ‡a Manchester Business School
- 510 2 _ ‡a Manchester Business School ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a University (Derby)
- 510 2 _ ‡a University of Liverpool
- 510 2 _ ‡a University of Liverpool ‡b Management School
- 510 2 _ ‡a University of Liverpool ‡b Management School ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a University ‡g Derby ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Atlas of Clinical Nuclear Medicine | |
The dynamics of industrial clustering in UK financial services | |
The economics and politics of international trade | |
Freedom and trade. | |
Influences on plant-level integration : some econometric evidence for the U.K. | |
The isotope bone scan: we can do better | |
Lateral collateral ligament tear of the knee: appearances on bone scintigraphy with single-photon emission tomography | |
Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI | |
Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism | |
Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. | |
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer | |
Metastatic thyroid carcinoma causing superior vena caval obstruction diagnosed on I-131 scan | |
Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer | |
Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumors. | |
Molecular Imaging in the Management of Adrenocortical Cancer: A Systematic Review | |
Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. | |
MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer | |
MRI or bone scan or both for staging of prostate cancer? | |
Multi-technique imaging of bone metastases: spotlight on PET-CT. | |
Multi-Tracer Guided PET Image Reconstruction | |
Multimodal Partial-Volume Correction: Application to 18F-Fluoride PET/CT Bone Metastases Studies | |
Neuron-specific enolase expression in multiple myeloma | |
New horizons in multimodality molecular imaging and novel radiotracers | |
Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features | |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis. | |
Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. | |
Oncological molecular imaging: nuclear medicine techniques. | |
Palatine tonsil SUVmax on FDG PET-CT as a discriminator between benign and malignant tonsils in patients with and without head and neck squamous cell carcinoma of unknown primary | |
Performance of different imaging modalities in assessment of response to neoadjuvant therapy in primary esophageal cancer. | |
PET/CT in non-small cell lung cancer staging-promises and problems. | |
PET/CT in oncology--a major advance. | |
PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management. | |
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers | |
Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. | |
The precision of textural analysis in (18)F-FDG-PET scans of oesophageal cancer | |
Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. | |
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging | |
Preparation and use of 131I magic gel as a dosimeter for targeted radionuclide therapy. | |
Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. | |
Progressive renal dysfunction despite successful renal artery angioplasty in a single kidney | |
Quantitative techniques in 18FDG PET scanning in oncology. | |
Radiomic analysis for response assessment in advanced head and neck cancers, a distant dream or an inevitable reality? A systematic review of the current level of evidence | |
Radiomics in esophageal and gastric cancer | |
Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer | |
Relationships of body habitus and SUV indices with signal-to-noise ratio of hepatic (18)F-FDG PET. | |
Renovascular disease. | |
Reply: Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with 18F-Fluoride | |
Review: Functional and hybrid imaging of bone metastases. | |
The role of 18F-FDG PET/CT in the management of testicular cancers. | |
The role of new PET tracers for lung cancer. | |
The role of nuclear medicine in monitoring treatment in skeletal malignancy. | |
The role of positron emission tomography in skeletal disease. | |
The Routledge companion to the geography of international business | |
Sentinel Lymph Node Biopsy in Pelvic Tumors: Clinical Indications and Protocols Under Investigation. | |
Skeletal metastases: what is the future role for nuclear medicine? | |
Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment | |
Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization | |
Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. | |
Systematic review of research design and reporting of imaging studies applying convolutional neural networks for radiological cancer diagnosis | |
Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. | |
Thyroid Paraganglioma: Our Experience and Systematic Review of the Literature on a Rare Tumor | |
UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging | |
UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. | |
Uncertainty-Aware Multi-resolution Whole-Body MR to CT Synthesis | |
The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI. | |
Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study | |
Validation of new image-derived arterial input functions at the aorta using 18F-fluoride positron emission tomography | |
The value of bone scintigraphy in the evaluation of osteoporotic patients with back pain. | |
Vertical integration in the UK petrol sector 1965-1990 | |
What can artificial intelligence teach us about the molecular mechanisms underlying disease? | |
What is the role of radionuclide sentinel lymph node biopsy and dissection in papillary thyroid cancer? | |
Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. |